Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc....
No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma SAN DIEGO, June 15, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc....
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.